Clinical trial
A Research Study to Check the Safety of NNC9836-0001 When Given to Healthy Participants and Participants With Type 2 Diabetes
NCT07896109 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.
Follow this trial by email Email me the PDF
Summary
Recruiting, started October 2026. Interventional study, Phase 1, 121 participants (estimated). Lead sponsor Novo Nordisk A/S; Germany. Primary measures: Single ascending dose (SAD): Number of Treatment emergent adverse events (TEAEs); Multiple ascending dose (MAD): Number of TEAEs.
How it compares
1,044 similar trials: same condition (Diabetes Mellitus, Type 2) and phase
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Research Study to Check the Safety of NNC9836-0001 When Given to Healthy Participants and Participants With Type 2 Diabetes
- Official title
- A Phase 1 Randomised, Double-blinded, Placebo-controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Doses of NNC9836-0001 Administered to Healthy Participants and Participants With Type 2 Diabetes
- Lead sponsor
- Novo Nordisk A/S
- Phase
- Phase 1
- Overall status
- Recruiting
- Start date
- October 22, 2026
- Completion date
- July 26, 2028
- Enrollment
- 121 (estimated)
- Sites
- 1
Conditions
MeSH condition names; the registry's own terms follow.
Who could take part, where it ran, who ran it
As filed in ClinicalTrials.gov.
- Sex
- All
- Minimum age
- 25 Years
- Maximum age
- 69 Years
- Healthy volunteers
- Yes
- Study type
- Interventional
- Sites
- 1
- Countries
- Germany
- Lead sponsor
- Novo Nordisk A/S
Arms
As registered; 2 arms.
| Arm | Type | Interventions |
|---|---|---|
| NNC9836-0001 | Experimental | NNC9836-0001 |
Show registry wordingParticipants will receive NNC9836-0001 subcutaneously. | ||
| Placebo | Placebo comparator | Placebo (NaCl) |
Show registry wordingParticipants will receive placebo subcutaneously. | ||
Primary endpoints
Registered primary outcome measures; 2 primary.
| Measure | Time frame |
|---|---|
| Single ascending dose (SAD): Number of Treatment emergent adverse events (TEAEs) | From dosing (day 1) until week 26 |
Show registry wordingMeasured as events. | |
| Multiple ascending dose (MAD): Number of TEAEs | From dosing (day 1) to week 34 |
Show registry wordingMeasured as events. | |
Lead sponsor's other trials
Novo Nordisk A/S, most recent start first.
+1,402 more trials See the organization page
Similar trials
Same condition (Diabetes Mellitus, Type 2) and phase, most recent start first.
+1,039 more trials See the condition page